A Pilot Trial of Ifetroban, A Thromboxane A2 Receptor Antagonist, in Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Ifetroban (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 27 Jun 2024 Planned End Date changed from 1 Jan 2025 to 1 Apr 2026.
- 27 Jun 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Apr 2025.
- 17 Jan 2024 Status changed from recruiting to active, no longer recruiting.